Form 8-K - Current report:
SEC Accession No. 0001140361-23-054630
Filing Date
2023-11-27
Accepted
2023-11-27 08:06:05
Documents
13
Period of Report
2023-11-27
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20015420_8k.htm   iXBRL 8-K 29335
2 EXHIBIT 99.1 ef20015420_ex99-1.htm EX-99.1 13736
  Complete submission text file 0001140361-23-054630.txt   188532

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA roiv-20231127.xsd EX-101.SCH 3862
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20231127_lab.xml EX-101.LAB 23290
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20231127_pre.xml EX-101.PRE 16550
7 EXTRACTED XBRL INSTANCE DOCUMENT ef20015420_8k_htm.xml XML 4365
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 231437343
SIC: 2834 Pharmaceutical Preparations